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Caveolin-1Once amyloid β peptides (Aβs) of the Alzheimer's disease build up in blood circulation, they are capable of bind-
ing to red blood cell (RBC) and inducing hemolysis of RBC. Themechanisms of the interactions between RBC and
Aβ are largely unknown; however, it is very important for the therapeutic target of Aβ-induced hemolysis. In the
present study, we investigated whether Aβ1–42 interacts with caveolin-1-containing detergent-resistant mem-
branes (DRMs) of RBC and whether the interaction could be modulated by dietary pre-administration of
docosahexaenoic acid (DHA). DHA pre-administration to rats inhibited hemolysis by Aβ1–42. This activity was ac-
companied by increased DHA levels and membrane ﬂuidity and decreased cholesterol level, lipid peroxidation,
and reactive oxygen species in the RBCs of the DHA-pretreated rats, suggesting that the antioxidative property
of DHA may rescue RBCs from oxidative damage by Aβ1–42. The level of caveolin-1 was augmented in the
DRMs of DHA-pretreated rats. Binding between Aβ1–42 and DRMs of RBC signiﬁcantly increased in DHA-rats.
When ﬂuorescently labeled Aβ1–42 (TAMRA-Aβ1–42) was directly infused into the bloodstream, it again occupied
the caveolin-1-containingDRMs of the RBCs from theDHA-rats to a greater extent, indicating that circulating Aβs
interact with the caveolin-1-rich lipid rafts of DRMs and the interaction is stronger in the DHA-enriched RBCs.
The levels of TAMRA-Aβ1–42 also increased in liver DRMs, whereas it decreased in plasma of DHA-pretreated
rats. DHA might help clearance of circulating Aβs by increased lipid raft-dependent degradation pathways and
implicate to therapies in Alzheimer's disease.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Amyloid beta peptides (Aβs) are central to the pathogenesis of
Alzheimer's disease (AD). The presence of Aβs in the plasma mem-
branes of red blood cells (RBCs) has recently attracted great interest be-
cause it may be useful as a potential peripheral biomarker for diagnosis
of AD [1]. RBCmembranes in AD patients are injured by unavoidable ex-
posure to Aβ1–42, suggesting an increased potential for breakdown of
erythrocyteswith liberation of hemoglobin (Hb) in the blood, called he-
molysis [2,3]. Degradations or dysfunctions of RBCs reduce the delivery
of oxygen to the brain. Kiko et al. [1] reported that human RBC Aβ1–40
andAβ1–42 levels increased and accumulated phospholipid hydroperox-
ideswith aging andAβs levels and accumulation of phospholipid hydro-
peroxides were decreased by antioxidant supplementation. However,β peptides; BW, body weight;
embranes; Dτ, diffusion time;
cemicroscope;Hb,hemoglobin;
Cs, red blood cells; ROS, reactive
hT, thioﬂavin T
shimoto).the mechanism(s) by which Aβ interacts with RBCs remains largely
unexplored.
Mature RBCs are devoid of receptor-mediated endocytosis because
they lack endocytic machinery [4]. Thus, it is very likely that the
receptor-independent docking of circulating Aβs occurs on the RBC
membrane, which affects the morphology and functions of RBC, as re-
ported in AD patients [1–3,5–7]. We hypothesize that Aβs affect RBCs
via caveolin-1-rich lipid rafts and/or caveolae. These microdomains
are implicated in a variety of signaling processes in cells [8–10]. The
lipid rafts can be functionally isolated as detergent-resistant mem-
branes (DRMs) [11]. In the present study we investigated whether
Aβ1–42 binds with DRMs isolated from RBC ghosts. Considering that
lipid raft size is well below the resolution limit of conventional micros-
copy [12], to characterize the binding property of Aβ1–42 with DRMswe
used ﬂuorescence correlation spectroscopy (FCS), a highly sensitive
method capable of single-molecule detection. FCS measures diffusion
time (Dτ) of ﬂuorescent probes in the confocal volume. Because higher
molecular weight increases the Dτ across the confocal volume, the ob-
served Dτ of free probe is much faster than that of probe bound to
lipid rafts [13–15]. In this study, 5-carboxytetramethylrhodamine-
labeled Aβ1–42 (TAMRA-Aβ1–42) was used as a ﬂuorescent probe and
mixed with DRMs to monitor Dτ. In addition, TAMRA-Aβ1–42 was
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localizes in DRMs of RBCs, with concurrent determination of the levels
of TAMRA-Aβ1–42 in the blood and liver.
Docosahexaenoic acid (DHA, C22:6 n-3) levels are remarkably re-
duced in RBC membranes of AD patients [16]. DHA supplementation
ameliorates cognitive deﬁcits and the brain amyloid burden of Aβ-
infused AD rat models [17–19]. DHA decreases membrane cholesterol
levels, affects fatty acid composition, and enhances antioxidative capa-
bility. These reports indicate that DHA changes membrane properties.
In this study, to examine whether the binding between Aβ1–42 and
DRMs could be affected by oral administration of DHA to rats, RBCs
from DHA pre-administered rats were incubated with Aβ1–42, followed
by hemolysis monitoring, fatty acid composition analysis, and oxidative
state analysis. DRMs from RBC ghosts were used to perform assays of
binding of Aβs by FCS and determine levels of caveolin-1.
2. Materials and methods
2.1. Animals
Wistar rats (generation 0, G0) (Jcl:Wistar; Clea Japan)were housed,
bred, andmaintained on a ﬁsh oil-deﬁcient diet (F-1®; Funabashi Farm)
and water ad libitum. Inbred 2nd-generation male rats (25 weeks old,
300–400 g bodyweight, [BW]) fed the same F-1 diet, were randomly di-
vided into two groups: the DHA group (n = 10) and the F1 control
group (n = 10). The DHA group was orally administered ethyl-ester
4,7,10,13,16,19-docosahexaenoate (Harima Foods, Inc., Osaka, Japan)
emulsiﬁed in 5% gum Arabic solution at 300 mg/kg BW/day, and the
control group was orally administered the same volume of 5% gum
Arabic solution alone. Oral administration of DHA emulsion and/or
gum Arabic solution was continued for 12 weeks.
All experiments were carried out in accordance with the Guiding
Principles for the Care and Use of Animals in the Field of Physiological
Science of the Physiological Society of Japan and approved by the insti-
tutional the Animal Care and Use Committee at Shimane University.
2.2. RBC preparation
After deep anesthesia with pentobarbital (50 mg/kg BW), whole
blood from individual rats was collected from the inferior vena cava
with a heparinized syringe. Half of the blood was used for preparation
of plasma and the other half was mixed with Locke's solution
(154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1 mM MgCl2, 3.6 mM
NaHCO3, 5 mM glucose, and 5 mM HEPES; pH 7.2) and pelleted at
300 g for 10 min in plastic tubes. The supernatant was discarded and
the RBCs were washed three times with the same solution. The buffy
coat and a portion of the upper layer of the RBCs were removed in
eachwash. The remaining RBCswere immediately subjected to hemoly-
sis assay or used for preparation of DRMs from ghost membranes.
2.3. Preparation of Aβ1–42 peptides and hemolysis assay
Because the Aβ1–42 displays an extraordinary aggregation pro-
pensity in aqueous buffer, both unlabeled Aβ1–42 and TAMRA-
Aβ1–42 were reconstituted initially to a concentration of 0.5 mM
in hexaﬂuoroisopropylalcohol (HFIP) to retain their monomeric state,
and then stored at−80 °C. Before use, HFIP was removed from the ali-
quots by blowing with N2 gas, and the Aβ1–42 was then mixed immedi-
ately with Locke's buffer. Then, RBCs (107 cells) suspended in 100 μL
Locke's buffer were mixed with the amyloid solution to a ﬁnal concen-
tration of 20 μMAβ1–42 or TAMRA-Aβ1–42 as desired. RBChemolysiswas
quantiﬁed by pelleting RBCs at 300 g for 10 min and determining the
amounts of Hb released into the supernatant by quantifying absorbance
of Hb at 405 nm; α-tocopherol was used as antioxidant during Aβ-
induced RBC hemolysis. Aliquots of 5 μL of the Aβ1–42-inducedhemolysis samples were subjected to confocal laser microscopy to visu-
alize the RBC morphology and the localization of the TAMRA-Aβ1–42.
2.4. Aβ1–42 ﬁbrillation
Aβ1–42 ﬁbrillation was assayed by thioﬂavin T (ThT) ﬂuorescence
spectroscopy as described [19,20] previously (see Supplementary
ﬁle 1).
2.5. Preparation of RBC ghost and DRMs
Washed RBCs were suspended in 40 volumes of ice-cold 5mMTris–
HCl buffer (pH 7.0), containing 1mMEDTA and centrifuged (18,000 g at
4 °C for 90 min). The supernatant was discarded and centrifugation at
30,000 g and 4 °C and washing were repeated until the ghost mem-
branes became whitish. Ghost membranes were stored at −80 °C
and/or extracted for DRMs. The detergent extraction of RBC ghosts
was performed as described previously [21–23] (see Supplementary
ﬁle 2).
2.6. Binding assay
The purpose of the TAMRA-Aβ1–42 binding assay is to demonstrate
that Aβ-receptors/target sites are present in reasonable numbers in
the DRMs isolated from RBC ghosts and are functioning with appropri-
ate afﬁnity for the TAMRA-Aβ1–42. The competitive binding experiment
measured the ability of increasing concentrations of unlabeled Aβ1–42 to
displace a single concentration of TAMRA-Aβ1–42 from the Aβ-receptor/
target sites. In brief, the 10 μg protein of DRMs in 100 μL mixed with
5 nM (100 μL) of TAMRA-Aβ1–42 were combined with increasing
concentrations of unlabeled Aβ1–42 (0–10 μM). After a brief ﬂush of
N2-gas, the mixture was incubated at 37 °C for 12 h to allow receptor/
target site binding of the Aβs to reach equilibrium. The assay tubes
then were centrifuged to pellet the DRMs. Aβ bound to the receptor/
target site will be retained in the DRM pellet, whereas unbound Aβ
will remain in the supernatant. One portion of the pelleted DRMs was
used for TAMRA-Aβ1–42 assay using a spectroﬂuorometer and the
other portion was used for the determination of unlabeled Aβ1–42 by
ELISA (see Supplementary ﬁle 3).
2.7. Immunoﬂuorescence and transmission electron microscopy
TAMRA-Aβ1–42 saturated binding DRMs samples were subjected to
ﬂuorescence laser microscopy to determine whether the TAMRA-
Aβ1–42 is bound to the surface and/or trapped inside theDRMs. Compet-
itive binding assay samples of DRMs (5 μL)were placed on a copper grid
and stained with 1% uranyl acetate, washed with distilled water, air
dried, and examined under a Hitachi H-7000 transmission electron
microscope (TEM) with an operating voltage of 75 kV.
2.8. ELISA
The amount of unlabeled Aβ1–42 bound with the DRMs was mea-
sured as previously described [20,24]. The levels of caveolin-1 in the
DRMs and cathepsin D in RBC ghosts also were measured by ELISA
(see Supplementary ﬁle 3). The levels of Aβ1–42 were calibrated using
standard Aβ1–42 solutions. The standard curve was linear in the range
of 0–400 pmol/100 μL/well. The absorbance of the control samples
was 4–5-fold higher than that of the background (blank) during the
ELISAs for caveolin 1 and cathepsin D; therefore, the results were
reliable.
2.9. Fluorescence correlation spectroscopy (FCS)
FCS was performed with a confocal volume element of 1 fL using a
Fluoro Point Light apparatus (Olympus, Tokyo, Japan). TAMRA and
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protein in 50 μL of 5 nM TAMRA-Aβ1–42) was monitored at room tem-
perature.When the volume element is projected onto theDRMs surface,
not only the bound TAMRA-Aβ1–42 diffusing at the DRMsurface but also
the unbound TAMRA-Aβ1–42 will be illuminated; thus, permitting the
detection of both slowly and rapidly moving amyloid species. The sam-
ple solution initially contained Aβmonomer,which diffused rapidly and
freely.
The sample solution after incubation contained Aβ bound to target
sites of DRMs, and the Aβ polymerized and formed larger masses that
diffused slowly. The diffusion times of these types of Aβ can be readily
distinguished with reference dyes; therefore, without any prior as-
sumption regarding the assembly types present in solution, the relative
abundance and diffusion time of assembled species can be inferred.
Differences in the diffusion times of Aβ in DRMs of RBCs isolated from
control and DHA rats were attributable to alterations in the masses
of the Aβ species, which could not have been formed without an in-
creased abundance in DRMs of RBCs. The details of principles of FCS
data evaluation are described in the Supplementary ﬁle 4.
2.10. Other in vitro methods
Membrane ﬂuidity of DRMs, fatty acid compositions and cholesterol
levels in RBC ghosts and DRMs, lipid peroxide (LPO) of DRMs, reactive
oxygen species (ROS) of RBC ghosts, and reduced glutathione (GSH) of
whole RBCs were determined as previously described [25–27], and are
brieﬂy described in the in the Supplementary ﬁle 5.
2.11. In vivo infusion of TAMRA-Aβ1–42
TAMRA-Aβ1–42 was infused into blood to determine whether
TAMRA-Aβ1–42 is localized in the DRMs of RBCs and/or TAMRA-Aβ1–42
occupancies of DRMs are modulated by the pre-administration of
DHA. After pentobarbital anesthesia, 2.0 mL of blood was initially
drawn from veins prior to infusion. Immediately after removing HFIP
from the TAMRA-Aβ1–42 aliquots using N2 gas, sterile buffer was
added, the samples were sonicated brieﬂy (approximately 2 s), and
then infused into the blood immediately. TAMRA-Aβ1–42 (100 pmol)
was infused through the left carotid veins and the incision was closed.
After 1 h the rats were sacriﬁced by bleeding, and levels of TAMRA-
Aβ1–42 in plasma, DRMs of RBC ghosts, and liver were determined. Pro-
tein concentrations were determined with a bicinchoninic acid protein
assay kit (Pierce Biotechnology, Rockford, IL).
2.12. Statistical analysis
Data are presented as mean ± standard error of the mean (SEM)
from at least three independent experiments. When necessary, one-
way ANOVA followed by Bonferroni's post hoc tests was used. Values
different at P b 0.05 were considered signiﬁcantly different.
3. Results
3.1. Fibrillation of Aβ1–42 in the Locke's solution used for hemolysis
The formation of amyloid ﬁbrils frequently relies upon the charac-
teristics of the buffers used for the ﬁbrillation process. We accordingly
investigatedwhether Aβ1–42 underwent ﬁbrillation processes in Locke's
solution (see Supplementary ﬁle 1), Aβ1–42 ﬁbers were clearly generat-
ed in the solution, suggesting that ﬁbrillogenesis deﬁnitely ensued in
the Locke's hemolysis solution. In the preliminary hemolysis experi-
ments, RBCs were incubated with (procedure i) pre-formed Aβ1–42
oligomers, (procedure ii) pre-formedmature Aβ1–42 ﬁbers, and (proce-
dure iii) Aβ1–42 monomers (immediately after HFIP was removed from
the aliquots). The pre-formed oligomers induced hemolysis, whereas
the ﬁbers did not (data not shown). In addition, procedure iii helpedinduced signiﬁcant hemolysis, suggesting that the “on-pathway” inter-
mediate oligomeric species that emerged during the ﬁbrillation of
monomers to ﬁbers in the hemolysis buffer were toxic and exerted he-
molytic effects on RBCs. Procedure iii helped maintain the oligomeric
species in amore functionally, physically, and conformationally uninter-
rupted and naïve state, as well as avoid the time-consuming and sensi-
tive preparation of oligomers while affording reproducible results.
3.2. Effects of pre-administered DHA on Aβ-induced hemolysis of RBC
Aβ1–42 induced hemolysis, and this induction was signiﬁcantly re-
duced in the presence of α-tocopherol (see Supplementary ﬁle 6, Fig
S2E). The hemolysis induced by Aβ1–42 was signiﬁcantly lower in the
RBCs from the DHA-pretreated rats than that in the control rats. The al-
leviation of hemolysis was accompanied by increased levels of GSH in
intact RBCs and decreased ROS in the RBC ghosts, and decreased levels
of LPO in the DRMs of DHA-pretreated rats. The levels of cathepsin D
were also signiﬁcantly higher in the ghost membranes of the DHA-
pretreated rats (Supplementary ﬁle 6).
3.3. Effects of pre-administered DHA on RBC ghosts and DRM lipid proﬁles
Lipid rafts are deﬁned as cholesterol- and sphingolipid-rich domains,
and manipulations of the levels of these lipids can be used to ascertain
raft function. The oral administration of DHA for 12 weeks signiﬁcantly
increased the levels of DHA and decreased the levels of cholesterol in
whole ghosts and DRMs (Table 1). The levels of plasma DHA were also
signiﬁcantly increased.
3.4. Effect of Aβ on RBC morphology
After it was conﬁrmed that the process of ﬁbrillation of Aβ1–42 oc-
curred in the hemolysis buffer, RBC suspensions were co-incubated
with or without freshly prepared monomeric Aβ1–42 to investigate the
interactions between Aβ and intact RBCs on the morphological level.
Microscopy revealed numerous blobs, bulges, and diffused membranes
with multiple leaks in the Aβ1–42-treated RBCs (Fig. 1, panel 1, B, inset
B1). In contrast, Aβ1–42-untreated RBCs exhibited clear demarcations
of their membranes (Fig. 1, panel 1, A, inset A1). The results were con-
sistent with increased hemolysis by Aβ1–42 (see Supplementary ﬁle 6).
When RBCs were incubated with ﬂuorescently labeled TAMRA-Aβ1–42,
they also underwent hemolysis similar to those with unlabeled
Aβ1–42. TAMRA-Aβ1–42 was found in the vicinity and/or on the surface
of plasma membranes of the RBCs (Fig. 1, panel 1, C, D, and E). The
pre-administration of DHA resisted the Aβ1–42-induced hemolysis of
RBCs (Fig. 1, panel 1, F).
3.5. Morphology and interactions of DRMs with TAMRA-Aβ1–42
Differential interference contrastmicroscopy revealed that themilky
white RBC ghost suspension consisted of empty sacs, which resembled
swollen red cells in form and size (see Supplementary ﬁle 7, Fig S3A
and its inset). In addition, DRMs spontaneously formed resealed
empty membranous sacs and appeared as swollen red cells in differen-
tial interference contrast microscopic ﬁeld (see Supplementary ﬁle 7,
S3B and its inset). TEM also showed that the DRMs were vesicle-like
structures with clear cut membrane bilayer architectures (see Supple-
mentary ﬁle 7, S3C).
TheDRMs sacs remained intact in the solution andwere used for the
binding assay of TAMRA-Aβ1–42/unlabeled Aβ1–42, FCS assay and
caveolin-1 measurement. Fluorescence observation demonstrated that
TAMRA-Aβ1–42 was discernible at the surface and/or inside the DRM
structures (Fig. 1, panel 2). These results were, at least partially, qualita-
tively consistentwith TEM,where some twisting and ribbon-like Aβ1–42
ﬁbers were evident at the surface and/or inside the DRM sacs (Fig. 1,
panel 3). The possibility that DHA affects the binding of TAMRA-
Table 1
Cholesterol (μg/mg protein) and fatty acid compositions (mol%) of plasma, RBC ghost and DRMs.
Plasma RBC ghost DRMs
F1 DHA F1 DHA F1 DHA
PLA 25.0 ± 0.5 26.0 ± 0.6 36.0 ± 1.1 36.5 ± 0.7 48.6 ± 0.8 48.0 ± 1.2
STA 12.0 ± 0.3 11.1 ± 0.4 21.3 ± 0.9 21.2 ± 1.0 19.0 ± 0.2 18.0 ± 1.0
OLA 16.5 ± 0.5 15.2 ± 0.7 8.8 ± 0.1 8.6 ± 0.3 7.0 ± 1.1 5.2 ± 0.3*
LLA 12.6 ± 0.3 19.3 ± 0.5* 5.2 ± 0.2 8.0 ± 0.3* 3.7 ± 0.1 4.5 ± 0.8
LNA 0.13 ± 0.01 0.20 ± 0.01* 0.05 ± 0.01 0.05 ± 0.01 0.03 ± 0.01 0.02 ± 0.01
AA 30.4 ± 1.0 12.0 ± 0.5* 22.4 ± 1.7 15.0 ± 0.8* 14.0 ± 0.4 7.5 ± 1.8*
EPA 0.14 ± 0.01 2.70 ± 0.16* 0.11 ± 0.04 0.80 ± 0.10* 0.05 ± 0.01 0.40 ± 0.08*
DPA 0.20 ± 0.02 0.60 ± 0.10* 0.40 ± 0.05 0.70 ± 0.05* 0.30 ± 0.02 0.40 ± 0.10
LGA 0.50 ± 0.01 0.40 ± 0.01 2.5 ± 0.1 2.9 ± 0.2 3.1 ± 0.3 3.4 ± 0.7
DHA 1.7 ± 0.1 12.1 ± 0.8* 1.3 ± 0.2 4.6 ± 0.4* 1.2 ± 0.1 2.5 ± 0.6*
NVA 0.40 ± 0.01 0.20 ± 0.01* 2.0 ± 0.1 1.8 ± 0.1 2.8 ± 0.3 2.0 ± 0.5
CHOL ND ND 522 ± 45 416 ± 26* 268 ± 15 221 ± 4*
Results aremean± SEM (standard error ofmean, n= 8–10). * P b 0.05. F1 vs DHA (Student's t-test). RBC, red blood cell; DRMs, detergent-resistantmembranes; PLA, Palmitic acid, C16:0;
STA, Stearic acid, C18:0; OLA, Oleic acid, C18:1 (n-9); LLA, Linoleic acid, C18:2 (n-6); LNA, Linoleinic acid, C18:3 (n-3); AA, Arachidonic acid, C20:4 (n-6); EPA, Eicosapentaenoic acid C20:5
(n-3); DPA, Docosapentaenoic acid, C22:5 (n-3); DHA, Docosahexaenoic acid, C22:6 (n-3); LGA, Lignoceric acid, C24:0; NVA, Nervonic acid, C24:1; CHOL, Total cholesterol. ND, Not
determined.
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were bound to DRMs of both the F1 control and DHA RBCs.
The effects of DHA on the binding of Aβ1–42 to DRMs of RBCs are
shown in Fig. 2, panel 1. The saturation of the binding of TAMRA-
Aβ1–42 to DRMs reached a concentration of 5–10 nM (Fig. 2A, panel 1).
A 5 nM TAMRA-Aβ1–42 was used, and then the effect of DHA on the oc-
cupancy of TAMRA-Aβ1–42 on DRMs was evaluated. DRMs on the RBCs
of DHA rats had a signiﬁcantly increased occupancy of TAMRA-Aβ1–42
as comparedwith those from control rats (Fig. 2B, panel 1). To examine
whether the binding to DRMs was speciﬁc to Aβ, the competitive bind-
ing of TAMRA-Aβ1–42 (5 nM) to DRMs vesicles in the presence of in-
creasing concentrations (0–10 μM) of unlabeled Aβ1–42 was examined.
Competition studies revealed that the amount of bound labeled
TAMRA-Aβ1–42 was reduced signiﬁcantly by the addition of unlabeled
Aβ1–42 (0–10 μM). With increasing concentrations of unlabeled
Aβ1–42, the amount of unlabeled Aβ1–42 measured by ELISA also in-
creased, suggesting that the binding of Aβ1–42 to the DRMswas speciﬁc.
Therefore, TAMRA Aβ1–42 was displaced from the binding/target sites
on DRMs by unlabeled Aβ1–42. Statistically signiﬁcant increases were
found with 3 and 10 μM Aβ1–42 (Fig. 2C, panel 1). The DHA-enriched
DRMs boundmore unlabeled Aβ1–42, as measured by ELISA. The afﬁnity
of the Aβ for DRMs was also calculated by ﬁtting the data to a one-site-
competition equation analysis, which revealed EC50 values of 9.55 and
6.78 nM, respectively, in the DRMs of F1 control and DHA rats. Compe-
tition studies showed that the amounts of labeled Aβ1–42 (TAMRA-
Aβ1–42) were signiﬁcantly reduced by the addition of unlabeled Aβ1–42
(0–10 μM). Accordingly, the amount of unlabeled Aβ1–42 measured by
ELISA was increased signiﬁcantly with the addition of ﬁxed amount of
labeled Aβ1–42, suggesting that the binding of Aβ1–42 to the DRMs was
speciﬁc. (Fig. 2C, panel 1).
The DHA-enriched DRMs had more (displaced) unlabeled Aβ1–42, as
measured by ELISA. The afﬁnity of the Abetas for DRMs was also
calculated by ﬁtting the data to a one-site-competition equation [Y =
Bottom + (Top− Bottom/(1 + 10(X − LogEC50))], where X = log (con-
centration) and Y= bound/unbound. The analysis revealed EC50 values
of 9.55 and 6.78 nM, respectively, in the DRMs of F1 control and DHA
rats (Fig. 2D, panel 1).
3.6. FCS
Free TAMRA-Aβ1–42 in solution and TAMRA-Aβ1–42 bound to DRMs
were observed by FCS. TAMRA diffused at approximately 100 μs
(Fig. 1, panel 2 A)., whereas TAMRA-Aβ1–42 alone (in the free form in so-
lution) diffused at approximately 260 μs. However, when the TAMRA-
Aβ1–42 was added to the DRMs, it exhibited two distinct, fast (τ1) and
slow (τ2), diffusion times. τ1 reﬂects the diffusion of the free form insolution from DRMs (τ1 was considered at approximately 260 μs) and
τ2 reﬂects diffusion of TAMRA-Aβ1–42 bound to DRMs. Based on ﬂuores-
cence intensity ﬂuctuations, the calculated τ2 values were 3228 ± 300
and 3485± 285 μs in the DRMs of control and DHA-pretreated rats, re-
spectively. The values in the DHA group (3485 ± 285 μs) tended to be
signiﬁcantly (P= 0.07) higher than those in the F1 control group. This
reﬂects an increased Aβ aggregation mass and/or increased accumula-
tion of TAMRA-Aβ1–42 with a resulting increased time for crossing the
volume element projected in the lipid rafts of DHA RBCs. (Fig. 2, panel
2, B).
3.7. Effect of DHA pre-administration on the caveolin-1 levels in the DRMs
As shown in Fig. 3A, in DRM fractions the levels of caveolin-1 were
also higher in the DRMs of DHA-pretreated rats. The highest increases
were found in fraction 3; that is, in the interface of a 35–40% sucrose so-
lution, indicating the asymmetric distribution of caveolin-1 in DRMs
(Fig. 3B).
3.8. Effect of DHA pre-administration on plasma, RBCs, and liver DRM
TAMRA-Aβ1–42 levels after TAMRA-Aβ1–42 infusion in vivo
TAMRA-Aβ1–42 was found in DRMs isolated from RBCs of TAMRA-
Aβ1–42 infused rats. The TAMRA-Aβ1–42 level in the DRMs of RBCs was
again higher in DHA-pretreated rats (Fig. 4C). More interestingly, the
levels of plasma TAMRA-Aβ1–42 were signiﬁcantly decreased in DHA-
pretreated rats (Fig. 4A), as compared with those of control rats, with
a corresponding increase in the levels of TAMRA-Aβ1–42 in DRMs isolat-
ed from the livers of DHA-pretreated rats (Fig. 4B). The decreases in the
plasma levels of TAMRA-Aβ1–42 were accompanied by rises in the pro-
tein levels of cathepsin D (protease activities) of both RBC ghosts (see
Supplementary ﬁle 6) and liver (Fig. 4D).
4. Discussion
The objective of this study was to investigate: i) whether dietary
DHA affects the interactions between Aβ1–42 and RBCs and hemolysis,
and then ii) the molecular mechanism involved in this effect. This
study showed that the RBC undergoes a morphological alteration
caused by interactions with Aβ, in agreement with previous studies
[1,28]. Dietary pre-administration of DHA reduced the hemolysis and
increased the accumulation of Aβs in RBC and liver lipid rafts, and RBC
and hepatic cathepsin D levels. These changes may contribute to the
clearance of circulatory Aβ1–42.
The hemolysis conferred by TAMRA-Aβ1–42 and/or unlabeled Aβ1–42
was signiﬁcantly lower in the RBCs of DHA-pretreated rats. Oxidative
Fig. 1. Panel 1: Effect of Aβ1–42 on RBC morphology and hemolysis. A, B: Represents effects of unlabeled Aβ1–42, while C, D and E represent that of the labeled Abeta (TAMRA-Aβ1–42), as
viewed in the confocal lasermicroscopic ﬁeld. Thus numerous blobs, bulges, and diffuse membranes withmultiple leakageswere seen in Aβ1–42-treated RBCs (B, inset B1, C, D, E). In con-
trast, control RBCs (Aβ1–42-untreated RBCs) did not become permeated and did not revealmembrane discontinuities, but it exhibited clear demarcations of theirmembranes (A, inset A1).
The results were consistent with increased leakage of hemoglobin from Aβ1–42-treated control RBCs (F). Panel 2: Confocal laser microscopic views of detergent-resistant membranes
(DRMs) incubated without (A, control) or with TAMRA-Aβ1–42 (B). The DRMs, which spontaneously formed membranous vesicles, also appeared as swollen red cells in the confocal
ﬁeld. Immunoﬂuorescence of TAMRA-Aβ1–42 was clearly discernible at the surface and/or inside the DRMs structures (B, C), as compared with the untreated (A) DRMs vesicles. (C): im-
munoﬂuorescence in the z-direction of the vesicles. Panel 3: Transmission electron microscopic (TEM) views of Aβ1–42-incubated DRMs samples. Some Aβ1–42-ﬁbers were visible in,
though not exclusively, the sacs of the DRMs (A, B, C, D, E; black arrows indicate the presence of amyloid ﬁbers). Some DRMs were found as grape-like clusters at or around (the branches
of) ﬁbers (F, G). H: Perseverance of DRMs-like vesicles in RBC ghost preparations stored at 4 °C for 2 days.
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membrane, therefore, appear to represent initiating events in hemolytic
cascades induced by Aβ. The reduction of hemolysis in the RBCs of DHA-
pretreated rats may be due to increased levels of antioxidants, including
GSH, decreased LPO, and ROS in the RBCs (see additional ﬁle 6).
Consistently with other reports [1,3], hemolysis was inhibited in the
presence of the antioxidant α-tocopherol.
The RBC concentration of Aβ1–42 increases in elderly people [1]. In
addition, it has been reported that Aβ1–40 and Aβ1–42 binds with, and/
or is taken up, by RBCs after in vitro incubation [6,29]. Moreover,
Aβ1–42 interacts with RBC more avidly than Aβ1–40 [1,6,30], because of
its increased propensity for aggregation [20] and two additionalhydrophobic amino acids at the C-terminus of Aβ1–42 that facilitates
penetration into the RBC bilayer [31]. In this study, microscopy revealed
a drastic change in RBC morphology by Aβ1–42, which was associated
with numerous blobs and diffused membranes with multiple leaks,
conﬁrming interaction between RBC and Aβs. These results were con-
sistentwith increased hemolysis byAβ1–42 treatment.Moreover, during
hemolysis, the interactions between RBC membranes and Aβ1–42 were
evident from the presence of TAMRA-Aβ1–42 at the vicinity of the RBCs.
We hypothesized that Aβ bindwith the DRMs in RBCs; however, the
identity of the structural domains of the DRMs that bind to Aβ1–42 has
remained obscure. The presence of DRMs in RBCs even in vivo is well
documented [32]. Recent evidence suggests that Aβ oligomers confer
Fig. 2. Panel 1: Effects of dietary pre-administration of DHA on the binding of Aβ1–42 on the DRMs of RBCs. A: Saturation of DRM-bound TAMRA-Aβ1–42 was obtained as a function of
TAMRA-Aβ1–42 concentration. Control DRMs were incubated overnight with different concentrations of TAMRA-Aβ1–42 (0–10 nM). Each data point represents the mean of triplicate de-
terminations of at least three separatemeasurements. B: The effects of DHA on the relative TAMRA-Aβ1–42 occupancy of DRMs after overnight incubationwere evaluated at aﬁxed (5 nM).
The DRMs of RBCs of DHA rats had signiﬁcantly increased (occupancy) levels of TAMRA-Aβ1–42 than those of control rats. C: Competitive binding/occupancy of TAMRA-Aβ1–42 (5 nM) to
DRMs vesicles with access of unlabeled Aβ1–42 (0–10 μM). Bound TAMRA-Aβ1–42 was displaced by unlabeled TAMRA-Aβ1–42. The DHA-enriched DRMs had more (displaced) unlabeled
Aβ1–42, as measured by ELISA. D: The afﬁnity of the Abetas for DRMs was also calculated by ﬁtting the data to a one-site-competition equation [Y = Bottom + (Top − Bottom/
(1 + 10(X-LogEC50))], where X = log (concentration) and Y = bound/unbound. EC50 values in the DRMs of F1 control and DHA rats were, respectively, 9.55 and 6.78 nM. * P b 0.05. F1
vs. DHA (Student's t-test). Panel 2: Autocorrelation (Gt) curves of ﬂuorescence ﬂuctuations of free 5-6-carboxytetramethylrhodamine (TAMRA) dye (A); TAMRA-Aβ1–42 free in solution,
TAMRA-Aβ1–42+DRMsof RBCs of F1 control andDHA-preadministered rats (B) after overnight incubation. The autocorrelation functions of free TAMRA and TAMRA-Aβ1–42 alone in buff-
er solution only were best ﬁtted with a one-component analysis model, and the respective diffusion times were estimated at approximately 100 and 260 μs (red ﬁtting curve). The auto-
correlation function of TAMRA-Aβ1–42 mixed with DRMs (TAMRA-Aβ1–42 + DRMs) samples was best ﬁtted with a two-component analysis model by ﬁxing the diffusion time (τ1) of the
free fraction TAMRA-Aβ1–42 at approximately 260 μs (red ﬁtting curve) and gave rise to the second component (τ2) of diffusion time, with respective values of 3228 ± 300 and 3485 ±
285 μs in the DRMs of F1 control and DHA rats.
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our study, TAMRA-Aβ1–42 consistently bound to DRMs in vitro and in
vivo. Considering that the binding of TAMRA-Aβ vs. unlabeled Aβs was
competitive, we showed that binding of Aβs to DRMs is to some extentFig. 3. Effect of dietary pre-administration of docosahexaenoic acid on caveolin-1 levels in lipid r
obtained by high-speed centrifugation (30 min, 4 °C, at 55,000 rpm in a TLA55 Beckman rotor)
gradient centrifugations. Fraction 1 represents fraction 1, above the 5% sucrose; Fraction 2 repre
from the interface between 35% and 40%; and Fraction 4 represents fraction 4, the sediment bespeciﬁc. The results were qualitatively consistent with available pub-
lished ﬁndings that Aβs accumulate appreciably in the DRMs of RBCs.
We considered the following points to assess themechanisms of the in-
teraction between Aβ and RBCs; (i) the RBCs have the only plasmaafts containing DRMs of F1 control and DHA RBCs. A: Levels of caveolin-1 in DRM fractions
. B: Levels of caveolin-1 in puriﬁed DRM fractions obtained from 5%, 35%, and 40% sucrose
sents fraction 2 from the interface between 5% and 30%; Fraction 3 represents the fraction
low the 40% sucrose layer. * P b 0.05. F1 vs DHA (Student's t-test).
Fig. 4. Effects of oral pre-administration of DHA on the levels of infused TAMRA-Aβ1–42 into blood plasma (A), DRMs of liver (B) andRBC (C), and hepatic cathepsinD protease enzyme (D);
cathepsin proteins were measured in the post-nuclear fraction of liver homogenates. * P b 0.05. F1 vs. DHA (Student's t-test).
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teins from intracellular sources, (ii) mature RBCs are unable to syn-
thesize new proteins, and (iii) RBC is a terminally differentiated
cell that completely lacks endocytic capability. Thus, the events trig-
gering binding of Aβ1–42 to RBCs must derive from pre-existing pro-
teins. In other words, the endocytosis-independent mechanismmust
exist for the interaction with the extracellular Aβs that are to be
taken up and/or bound on the surface of RBCs, as reported earlier
[1,29].
DRMvesicles displayed Aβs putatively boundon their surface and/or
accumulated inside them (Fig. 2). The above ﬁndings suggest that DRMs
proteins are engaged in interaction with the Aβs. We accordingly spec-
ulate that one of the candidates that affect the interactions between Aβs
and DRMs is caveolin-1. Consistently with this notion, the presence of
caveolin-1 has been reported in RBC [34]. Irrespective of the mecha-
nism(s), i) Aβ binds with caveolin-1-containing lipid rafts of RBCs and
is subjected to protease degradative enzymes present on or bound to
their own surfaces, and/or ii) RBCs, via their lipid raft pockets, transport
and deliver the Aβs to the liver for detoxiﬁcation by hepatic proteolytic
enzymes such as cathepsin D. However, TAMRA-Aβ was not enriched/
associated with DRMs uniformly. Although the exact reason for this
is unclear, we hypothesize that Aβ1–42 accumulates in caveolin 1-
containing DRMs. The highest caveolin 1 levels were present in
DRMS in fraction 3 of the sucrose gradient. Therefore, it is possible
that there are subsets of DRMs that harbor varying amounts of cave-
olin 1, and hence TAMRA-Aβ1–42. We speculate that this might ex-
plain why TAMRA was not enriched in the DRMs uniformly. DHA
increased DRM ﬂuidity (see Supplementary ﬁle 8) with concomitant
decreases of cholesterol and increases of DHA levels in DRM domains
(Table 1). Increased membrane ﬂuidity facilitates endocytosis-like
events. DHA increases both lateral and translational membrane ﬂu-
idity of the lipid bilayer [18,25]. Therefore, it is very likely that a
DHA-induced increase in ﬂuidity accelerates the lateral movement
of individual rafts within DRMs. Thus, it can be speculated that
DHA might have facilitated the accommodation of caveolin-1 in the
lipid raft platforms and/or stabilized the association between
caveolin-1 and Aβ, thereby concentrating them for degradation.
This speculation is consistent with the results of real-time monitor-
ing by FCS of the interactions and dynamic behaviors of TAMRA-
Aβ1–42 with the DRMs of RBCs of DHA-pretreated rats. In the present
study, we also demonstrated that levels of caveolin-1 increased, ac-
companied with increased TAMRA-Aβ1–42 levels in the DRMs of
RBCs and liver of the DHA-pretreated rats. The levels of Aβs in the
plasma were decreased. These results indicate that DHA increased
the binding of Aβ1–42 to DRMs in RBCs via caveolin-1-rich lipid
rafts or caveolae of the DRMs and were transported to the liver,
which decreased the plasma level of TAMRA-Aβ1–42 after infusion.5. Conclusions
The results of the present study are consistent with the hypothesis
that the enrichment of DHA in RBCs might ameliorate the plasma bur-
den of amyloids. In conclusion, alterations in morphology originated
from modiﬁcations caused by toxic oligomeric Aβ interactions with
RBCs, and these interactions involved caveolin-1-rich lipid rafts. How-
ever, these RBC-disrupting interactions were ameliorated by the pre-
administration of DHA by antioxidation and change in the membrane
properties of RBC. This is the ﬁrst report that DHA enhances the clear-
ance of Aβ1–42 in the plasma and suggests that DHA supplementation
can help to prevent the risk of AD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.03.008.
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